Immune-mediated hemolysis is a well-recognized occurrence which complicates the period following a bone marrow transplant (BMT). However, although many studies have investigated the hemolytic anemia following ABO-incompatible BMT, data regarding the occurrence of alloantibodies against red blood cell (RBC) antigens other than ABO in patients undergoing hematopoietic stem cell transplantation are limited. In this review, we briefly analyze the most important non-ABO red blood cell (RBC) antigen systems involved in the development of post-BMT alloimmune hemolytic anemia, paying particular attention to the pathogenic mechanisms and the clinical significance of the alloantibodies involved. Among the non-ABO RBC antigens, RhD antigen is the one most frequently implicated in the development of post-BMT alloimmune hemolytic anemia. Although less frequent than hemolysis following transplants with ABO incompatibility, non-ABO-incompatible allograft hemolysis may severely complicate the post-BMT period creating difficult clinical management issues. For this reason, we advise careful pre-transplant donor and recipient checks for the most important RBC antigen systems and close post-BMT immunohematological monitoring in those patients undergoing allogeneic hematopoietic stem cell transplant with RBC antigen incompatibility.
Immune-mediated hemolysis is a well-recognized occurrence which complicates the period following a bone marrow transplant (BMT). However, although many studies have investigated the hemolytic anemia following ABO-incompatible BMT, data regarding the occurrence of alloantibodies against red blood cell (RBC) antigens other than ABO in patients undergoing hematopoietic stem cell transplantation are limited. In this review, we briefly analyze the most important non-ABO red blood cell (RBC) antigen systems involved in the development of post-BMT alloimmune hemolytic anemia, paying particular attention to the pathogenic mechanisms and the clinical significance of the alloantibodies involved. Among the non-ABO RBC antigens, RhD antigen is the one most frequently implicated in the development of post-BMT alloimmune hemolytic anemia. Although less frequent than hemolysis following transplants with ABO incompatibility, non-ABO-incompatible allograft hemolysis may severely complicate the post-BMT period creating difficult clinical management issues. For this reason, we advise careful pre-transplant donor and recipient checks for the most important RBC antigen systems and close post-BMT immunohematological monitoring in those patients undergoing allogeneic hematopoietic stem cell transplant with RBC antigen incompatibility. Hemolysis is a well-recognized complication of allogeneic bone marrow transplantation (BMT) and may be caused by immune and nonimmune mechanisms. Post transplant immune-mediated hemolysis may be the result of autoimmune effects, passenger lymphocyte syndrome, major and minor blood group incompatibility but, not rarely, more than one type of mechanism is involved. 1 Alloimmune hemolytic anemia (AHA) following major and minor ABO-mismatched allogeneic hematopoietic stem cell (HSC) transplantation is one of the most common and dangerous immunohematological complications of this procedure. 2 Less frequently, other RBC antigen systems, in most cases those of the Rh system, have been implicated in the development of AHA. 1 However, although the hemolytic complications following ABO-incompatible BMT have been investigated by several authors, 2 only few reports, almost anecdotally, have described the immunohematological complications following non-ABO incompatible transplants. In this review, we briefly report the most important non-ABO RBC antigen systems implicated in post transplant AHA and analyze their clinical significance.
Incidence of non-ABO RBC alloantibodies after allogeneic BMT
Only few data are available in the published literature on the frequency of non-ABO red cell alloimmunization in the post transplant setting. [3] [4] [5] [6] [7] Ting et al 3 described the production of non-ABO red cell alloantibodies in 13 of 150 patients (8.7%) after BMT. However, examining the series carefully, only nine of the 150 (6%) had non-ABO alloantibodies that had developed during the post-BMT period. Abou-Elella et al 4 found that two of 45 patients (4.4%) who received an allogeneic BMT developed non-ABO alloantibodies after the transplantation. De la Rubia et al 5 recently reported a similar frequency (3.7%) in a series of 217 patients undergoing allogeneic hemopoietic peripheral cell transplantation and also identified ABO incompatibility and patient's age as the only two variables significantly associated with the development of non-ABO RBC alloantibodies. In a retrospective analysis of the blood bank records of 427 allogeneic HSC transplant recipients seen between 1994 and 1999, Young et al 6 observed a very low incidence (nearly 1%) of post-BMT non-ABO/RhD red cell alloantibodies. If the incidence of such alloantibodies in the post-BMT period is low, the frequency with which they cause clinically significant immune hemolysis seems to be even much lower. In fact, Hows et al 7 found that only one out of the four patients with post-BMT antiRh alloantibodies developed clinical hemolysis. However, although rare, hemolytic episodes have often been described as severe. 1, 7 Table 1 summarizes the most important non-ABO RBC group antigen systems involved in the development of clinically significant post-BMT alloimmune hemolytic anemia.
Incompatibility involving the Rh system
Among the non-ABO red cell antigen systems, the Rh system is the one most frequently implicated in the development of post transplant AHA. 1, 8 Mismatching of the Rh system has different features from ABO mismatches. 9 In fact, as the anti-Rh alloantibody does not occur naturally, we consider a major or minor Rh incompatibility only when either the recipient or the donor has antibodies following a previous exposure (eg pregnancy and/or transfusions). Although bone marrow transplants with Rh incompatibility involving C, c and E antigens have been described in the medical literature, 7,10,11 most reports regard the D antigen. [12] [13] [14] [15] [16] Like ABO incompatibility, RhD incompatibility can cause hemolytic anemia after BMT. 9 A major RhD incompatibility between donor and recipient of a BMT may lead to a severe delayed hemolytic anemia. 15 Panhypoplasia was observed in a patient following a major RhD incompatible BMT with marrow recovery after the subsequent spontaneous reduction in the anti-RhD titer. 17 A minor RhD incompatibility can cause both immediate and delayed hemolysis, the former being due to anti-RhD alloantibodies produced by lymphocytes infused with the donor marrow (passenger lymphocyte syndrome) and the latter being due to anti-RhD alloantibodies produced by donor engrafted lymphocytes. 7 A simultaneous mismatch involving both ABO and Rh systems can also occur and may cause hemolysis and/or pure red cell aplasia in the post transplant period. 7, 18 RhD incompatibility is treated in the same way as ABO incompatibility, in order to prevent post transplant hemolysis. 9 Thus, in the case of RhD major incompatibility (alloimmunized RhD-negative recipient and RhD-positive donor), RBC must be removed from the donor's bone marrow by sedimenting substances such as hydroxyethyl starch (HES). Other strategies include recipient plasma exchange, in order to reduce the anti-D titer. In the case of RhD minor incompatibility (ie, when the donor plasma contains anti-RhD antibodies against recipient red blood cells), plasma must be removed from the donor's bone marrow. It has also been proposed that patients undergoing BMT with incompatibilities involving the RhD system should receive prophylaxis with infusion of Rh-negative blood or anti-RhD immunoglobulins. An antiRhD antibody does not necessarily pre-exist, since it may be produced during the BMT due to the mismatch between the donor and recipient. A RhD-positive bone marrow recipient may develop anti-RhD antibodies following transplant if the donor is RhD negative. The recipient's residual RBC (RhD positive) may be sufficiently numerous to stimulate the donor's engrafted lymphocytes. 1 However, this event occurs only rarely since the donor-related primary immune response usually starts about 6 months after BMT and after this period, if recipient bone marrow is 100% of donor origin, residual RhD-positive recipient RBC are no longer detectable. 19 It is also unlikely that the reverse situation (RhD-negative recipient and RhD-positive donor) may develop a de novo anti-RhD antibody, since the recipient lymphocytes (the only cells capable of producing anti-RhD antibody) are destroyed by the conditioning treatment. However, if mixed erythrocyte chimerism persists after the BMT, severe hemolytic anemia due to the development of autoantibodies with donorantirecipient specificities for non-ABO system RBC antigens may complicate the post transplant period. 8 Another occurrence in the BMT setting is alloimmunization, in patients receiving RhD-negative bone marrow transplants, against platelet concentrates from RhD-positive donors. This event seems to be not uncommon: the incidence of anti-RhD antibodies in oncohematologic patients who underwent autologous BMT and received platelet transfusions seems to be nearly 20%. 20 For this reason, some authors suggest prophylaxis with intravenous anti-RhD immunoglobulins during platelet transfusions in such patients in order to prevent alloimmunization against RhD. 21 Conversely, other authors found a low incidence of anti-D alloimmunization in hematologic patients receiving D-incompatible platelet transfusions. [22] [23] [24] A BMT recipient with a pre-existing anti-RhD alloantibody must be transfused with RhD-negative RBC until the disappearance of the alloantibody has been documented by the indirect antiglobulin test (IAT) and the cross-match with RhD-positive RBC becomes negative. 9 Alloantibodies directed against other components of the Rh system include anti-C, anti-c and anti-E antibodies. 3, 8, 11 Usually, these antibodies are not isolated but are associated with anti-D or antibodies against other red cell antigen systems, 3 and may trigger or worsen a hemolytic picture. Table 1 Non-ABO red blood cell group antigen systems involved in the development of post-BMT alloimmune hemolytic anemia
RBC antigen system Antibodies

Mechanism of hemolysis
Rh system Anti-D, -C, -c, -E Delayed hemolytic anemia, 13, 21, 32 which may be severe after major Rh-mismatched grafts. 15 Passenger lymphocyte syndrome 7 and chronic hemolysis (in the case of persistence of mixed chimerism) 8 have also been described Kell system Anti-Kell Delayed hemolytic anemia 25, 28 Kidd system Anti-JK a , -JK b
Severe acute hemolytic anemia with intravascular hemolysis (passenger lymphocyte syndrome), 6, 29 delayed hemolytic anemia 25 MNSs system Anti-M, -N, -S, -s Delayed hemolytic anemia 6, 25 Lewis system Anti-Lewis 
Incompatibility involving other blood group antigens
Pre-transplant clinical consideration is usually given only to ABO and RhD compatibility between donor and recipient. Although immune hemolysis due to ABO or RhDmismatched marrow transplants is the most frequent immunohematological post-BMT complication, occurring in approximately 10-15% of such transplants, 6 other RBC antigen systems have been implicated less frequently in alloimmunization after allogeneic transplantation. [25] [26] [27] [28] [29] [30] However, the medical literature reports many cases of hemolysis after BMT caused by alloantibodies directed against the Kidd, MNSs and Kell antigen systems. 6, 25, [28] [29] [30] The hemolysis may be severe if several alloantibodies are simultaneously involved. 25 We have previously described 28 an episode of mild hemolytic anemia 1 month after BMT due to a major Kell incompatibility (recipient with antiKell alloantibodies, donor Kell negative). Of the non-ABO/ Rh alloantibodies, those directed against the Kidd antigen system are among the more frequently observed and are often associated with severe intravascular hemolysis. 25, 29, 30 They may cause acute hemolysis through a passenger lymphocyte mechanism 25, 29 or, if mixed erythrocyte chimerism persists, they can be responsible for a delayed hemolytic anemia. 29 Young et al 6 described two cases of post transplant acute intravascular hemolysis due to antiJk a antibodies produced by donor-derived passenger lymphocytes, successfully treated in one case with plasma exchange and in the other case with steroids and red cell exchange. The Lewis antigen system needs particular consideration. In fact, while a successful BMT leads to the appearance of donor-type red cell antigen systems such as ABO, Rh, Duffy, Kell, MNSs, donor erythrocytes continue to express recipient-type Lewis antigens even during the post transplant period because the cells do not synthesize these antigens but adsorb them from plasma. 1, 31 There are reports 5, 26 of post transplant hemolytic anemia due to acquired anti-Lewis antibodies in Lewis-mismatched bone marrow transplants. Some authors 27 postulated that Lewis incompatibility may contribute to the renal failure complicating allogeneic BMT.
Conclusions
Patients undergoing non-ABO mismatched allogeneic BMT are at risk of developing alloantibodies against non-ABO RBC antigens. Although rarely, the antibody formation may complicate the post transplant period by causing clinically significant hemolysis. If hemolysis occurs, it is often severe.
For this reason, we advise pre-transplant donor and recipient checks of Rh phenotype and of the other erythrocyte antigen systems involved in post-BMT alloimmune hemolytic anemia (Kell, Kidd, MNSs, Lewis). Moreover, the clinical implications of the immunohematological aspects of BMT highlight the importance of close immunohematological monitoring in allogeneic bone marrow transplants when there are Rh or other red cell antigen mismatches between the donor and recipient. However, long-term follow-up is needed since immunohematological complications may develop even many years after BMT. 32 Immunohematological follow-up is also important for monitoring marrow engraftment and disease status. In fact, following an ABO-matched BMT, it is possible to identify a chimeric antigen of Rh or other red cell group systems whose appearance/disappearance in the post transplant period gives the opportunity to evaluate the marrow engraftment. Furthermore, whereas persistence of the recipient's blood group antigens in the post transplant period suggests that the conditioning regimen failed to eradicate the patient's marrow, the reappearance of the recipient's blood group antigens may indicate a relapse of the disease. 1 Since these data are very important for the hematologist, close cooperation between clinical and laboratory staff in a BMT unit is warranted.
